TNDM

Tandem Diabetes Care, Inc.

Tandem Diabetes Care Inc is a provider of medical care devices in the United States. Its products aid in the delivery of insulin and getting accurate readings through its software application.

Tandem Diabetes Care, Inc. (TNDM) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B-); its weakest is Value (D+). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
D+
Factor Score 1.5 / 5.0
Growth
B-
Factor Score 3.1 / 5.0
Profitability
B-
Factor Score 2.9 / 5.0
Momentum
B-
Factor Score 3.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 210.6
EV / EBITDA -231.5
Rev Growth YoY 13.8%
Gross Margin 56.6%
Price Return 3M -9.8%
Price Return 12M 11.1%
Catalyst Signal 0.00
Market Cap $1.4B
TTM Revenue $1.1B
Price / Sales 1.3
ROE -36.7%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 D+ (1.5) B- (3.1) B- (2.9) B- (3.0) C+ (2.6) C+ (2.6)
2026-11-08 C- (1.9) B (3.2) B- (2.9) C (2.4) C+ (2.6) C+ (2.6)
2026-11-01 D+ (1.6) B- (3.1) C+ (2.8) C+ (2.5) C+ (2.7) C+ (2.5)
2026-10-25 D+ (1.8) B- (3.1) C+ (2.8) C (2.3) C+ (2.6) C+ (2.5)
2026-10-18 C- (1.9) B- (3.1) C+ (2.8) C (2.4) C+ (2.6) C+ (2.6)
Page 1 of 8
…